Drug Profile
Inclacumab - Global Blood Therapeutics
Alternative Names: DSM ACC2641; LC1004-002; PF-07940370; R 1512; RG1512; RO 4905417Latest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator Genmab; Roche
- Developer Global Blood Therapeutics; Roche
- Class Anti-inflammatories; Anti-ischaemics; Cardiovascular therapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action P selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Sickle cell anaemia; Vaso-occlusive crisis
- Discontinued Acute coronary syndromes; Myocardial infarction; Peripheral vascular disorders
Most Recent Events
- 24 Nov 2023 Pfizer completes a phase III trial in Vaso-occlusive-crisis (In adolescents, In children, In the elderly, In adults) in USA, Italy, Kenya, Lebanon, Oman, Turkey, Germany, Italy, Brazil, Colombia, France, Nigeria, Saudi Arabia, United Kingdom, Zambia (IV) (NCT04927247) (EudraCT2020-005287-60)
- 05 Oct 2022 Global Blood Therapeutics has been acquired by Pfizer
- 09 Jun 2022 3695738: No updates